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Abstract Loss-of-function mutations in the multifunctional
growth factor progranulin (GRN) cause frontotemporal
lobar degeneration (FTLD) with TDP-43 protein accumu-
lation. Nuclear TDP-43 protein with key roles in RNA
metabolism is also aggregated in amyotrophic lateral
sclerosis (ALS), suggesting that ALS and FTLD constitute
a broad disease continuum. However, the fact that muta-
tions in GRN are associated with FTLD, while mutations in
TDP-43 cause a preferential loss of motor neurons resulting
in ALS-end of the disease spectrum, suggests involvement
of both cell-autonomous and non-autonomous mechanisms.
Studies on animal models and in vitro studies have been
instrumental in understanding the link between GRN and
TDP-43 and also their role in neurodegeneration. For
instance, in mouse models, allelic deficiencies of Grn do
not recapitulate human pathology of TDP-43 brain accu-
mulations, but embryonic neurons derived from these mice
do show abnormal TDP-43 accumulation after additional
cellular challenges, suggestingthat TDP-43 changes observed
in GRN mutation carriers might also relate to stress. Recent
results have shown that the dual action of GRN in growth
modulation and inflammation could be due to its negative
regulation of TNF-α signaling. In addition, GRN also
interacts with sortilin and is endocytosed, thereby regulating
its own levels and possibly also modulating the turnover of
other proteins including that of TDP-43. Accumulating
evidence suggests that TDP-43 abnormal cellular aggrega-
tion causes a possible gain of function, also suggested by
recently constructed mouse models of TDP-43 proteinopathy;
however, it would be inconvincible that sequestration of
physiological TDP-43 within cellular aggregates observed in
patients would be innocuous for disease pathogenesis. This
review discusses some of these data on the possible link
betweenGRNandTDP-43aswellasmechanismsinvolvedin
TDP-43-led neurodegeneration. Continued multitiered efforts
on genetic, cell biological, and animal modeling approaches
would prove crucial in finding a cure for GRN-related
diseases.
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FTLD—Progranulin
Frontotemporal dementia (FTD) is the second most common
formofcorticaldementiainthepopulationundertheageof65
with a prevalence of 3–25 cases per 100,000 people
(Ratnavalli et al. 2002). Clinical FTD is characterized by
changes in personality/behavior and/or language dysfunc-
tion, but patients may also display movement abnormalities
such as Parkinsonism or motor neuron disease (Brun et al.
1994; Neary et al. 1998). The neuropathology associated
with FTD and other closely related clinical entities such as
progressive non-fluent aphasia and semantic dementia is
heterogeneous but shares a feature of relatively selective
degenerationofthefrontalandtemporallobes(frontotemporal
lobar degeneration, FTLD) (Trojanowski and Dickson 2001;
Mackenzie et al. 2009). Many patients of FTD showing tau
deposits (FTLD-τ) and mutations within the microtubule-
associated protein tau (MAPT) gene were earlier identified in
these FTLD-τ families linked to chromosome 17q21-22
(Hutton et al. 1998; Spillantini et al. 1998; Poorkaj et al.
1998). However, the nontauopathy disorders where ubiquiti-
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of neuronal and glial cells have been shown to be much
more common and also representing a clinically, genetically,
and pathologically highly heterogeneous group (FTLD-U)
(Josephs et al. 2004;H o d g e se ta l .2004; Mackenzie et al.
2009; Seelaar et al. 2011).
The past few years witnessed enormous progress in
understanding the pathological complexity and in identifying
the genetic etiologiesofthis complexdisorder. Intense genetic
studies led to the identification of valosin-containing protein
gene (VCP)o nc h r o m o s o m e9 p 2 1 - p 1 2( W a t t se ta l .2004)
and the charged multivesicular body protein 2B gene
(CHMP2B)o nc h r o m o s o m e3 p 1 3( S k i b i n s k ie ta l .2005).
VCP and CHMP2B are involved in protein turnover in
ubiquitin–proteasome (Ub–Pr) and/or endososome–lysosomal
pathways underscoring the importance of a proper protein
turnover for neuronal function and viability (Babst et al. 2002;
Gitcho et al. 2009b). However, it was the landmark discovery
of progranulin/GRN mutations in the remaining FTLD-U
families in 2006 (Baker et al. 2006; Cruts et al. 2006)t h a t
was crucial in so many respects. First, it turned out that GRN
mutations are the commonest causal genetic factor responsi-
ble for up to 10% of the FTD cases (Baker et al. 2006;C r u t s
et al. 2006). Second, identification of GRN mutations was
particularly intriguing as it provided an explanation for the
amazing coincidence of the presence of two important genes
on chromosome 17q21-22 linked to the same disease
phenotype. Lastly, GRN with a well-known prior role in
cancer stands out as a textbook example where a molecule
could be causally linked to two extreme ends of a disease
spectrum, on one end of which is somatic cancer with
uncontrolled division and, on the other, degeneration of
postmitotic neurons. This suggests that “subtle” growth
modulators, deficiency of which is not embryonically lethal
or developmentally challenging, should be further explored
for their involvement in age-related neurodegeneration. It also
now appears that those afflicted with a neurodegenerative
disorder have a reduced incidence of cancers and vice versa
(Plun-Favreau et al. 2010).
GRN was independently isolated by several laboratories
(Plowman et al. 1992; Zhou et al. 1993; Baba et al. 1993)
as a 593-amino-acid-secreted glycoprotein composed of a
signal peptide followed by 7.5 tandem repeats of a 12-
cysteinyl granulin motif that can be proteolytically cleaved
to form a family of 6-kDa granulin peptides (grn) (He and
Bateman 2003)( F i g .1a). Both GRN and grn-peptides serve
as multifunctional secreted growth factors playing key roles
in development, cell cycle progression, cell motility, neuritic
outgrowth, wound repair, and inflammation (He and Bateman
2003; Van Damme et al. 2008; Ahmed et al. 2007). GRN is
expressed in a wide variety of tissues including neurons of
cerebral cortex, hippocampus, and cerebellum (Daniel et al.
2000; Ahmed et al. 2007)( F i g .2a). A high expression of
GRN is also noted in a great variety of cancer cell lines as
well as in clinical specimens of breast, ovarian, and renal
cancers and in glioblastomas (Liau et al. 2000;H ea n d
Bateman 2003). Although ultrastructural studies identified the
fibrillar nature of the FTLD-U inclusions (Pirici et al. 2006;
Fig. 1 Progranulin and TDP-43
structure and processing. a The
top part of the figure represents
the progranulin protein (human
GRN; rodent Grn) and the
bottom part shows the consensus
sequence of the processed
granulin peptides (grn); A–G
represent granulin peptides and
p represents paragranulin. b
Structure of TDP-43 showing
different domains of the protein
and select mutations mostly
clustered in the glycine-rich C
terminus of TDP-43. The lower
panel shows TDP-43 processing
into ∼35-kDa and different ∼25-
kDa species identified or specu-
lated to exist in human FTLD/
ALS patients. Drawn to scale
562 J Mol Neurosci (2011) 45:561–573Lin and Dickson 2008), the building blocks of the ubiquiti-
nated protein(s) remained unknown (Forman et al. 2006;
Pirici et al. 2006).
TDP-43 as a Molecular Substrate in FTLD and ALS
It was yet another coincidence that the principal component
of ubiquitin
+ inclusions in FTLD-U that had hitherto eluded
us for so long was also identified in the year 2006 by
biochemical enrichment techniques as TAR DNA-binding
protein (TDP-43) (Neumann et al. 2006; Arai et al. 2006)
(Fig. 2b).
TDP-43 is a 43-kDa or 414-amino-acid nuclear protein,
encoded by the TARDBP gene on chromosome 1. The gene
was initially cloned from a genomic screen for cellular
factors that bind to the TAR DNA of HIV type 1 (Ou et al.
1995) and was also identified independently as part of a
complex involved in the splicing of the cystic fibrosis
transmembrane conductance regulator gene (Buratti and
Baralle 2001). As a member of the heterogeneous ribonu-
cleoprotein (hnRNP) family, TDP-43 subserves a variety of
functions in regulation of transcription and splicing and in
RNA stability, functions that might be as diverse and
perhaps more critical than those subserved by GRN (Buratti
and Baralle 2008; Lagier-Tourenne et al. 2010). TDP-43 is
composed of two tandem RNA recognition motifs (RRM1
and RRM2) followed by a glycine-rich carboxyl terminus
(Fig. 1b). Both RRMs retain nucleic acid binding proper-
ties, yet only RRM1 appears essential for RNA splicing
(Buratti and Baralle 2001). In addition, the protein also has
a nuclear localization signal and a nuclear export signal as
TDP-43 shuttles continuously between nucleus and cyto-
plasm (Ayala et al. 2008).
Interestingly, TDP-43 was not only a core component of
the neurodegenerative mechanism(s) involved in FTLD-U
(now called FTLD-TDP) but also in ALS and ALS–FTLD,
further strengthening the premise that ALS and FTLD are
part of a broad disease continuum (Neumann et al. 2006;
Arai et al. 2006; Mackenzie et al. 2009). Recent studies
have shown that TDP-43 pathology could also be observed
in a spectrum of other neurodegenerative disorders,
including Alzheimer’s disease (AD), Guam Parkinson
dementia complex, and Lewy body disease (Dickson
2008). For instance, ∼30% of AD patients show TDP-43
pathology, suggesting that TDP-43 might have even a
broader role in neurodegeneration (Dickson 2008). Thus,
2006 was a fruitful year bringing a major shift in our
understanding of FTLD pathogenesis and setting a stage for
functional studies to understand how GRN causal mutations
lead to TDP-43 pathology and downstream events.
GRN Has a Loss-of-Function Disease Mechanism
Mechanistically, the simplest piece in the FTLD-TDP patho-
genesis puzzle isthatGRNcausalmutationscause a lossofits
function. All mutations described so far in GRN have been
either simple loss-of-function mutations or mutations that
likely render GRN less active or ineffective. The first type of
GRN mutations are complete or near-complete deletions of
GRN gene (Gijselinck et al. 2008; Rovelet-Lecrux et al.
2008). The second types are those where the transcripts do
not leave the nucleus, such as splice-donor site mutations
Fig. 2 Progranulin and TDP-43
immunoreactivity in human and
rodent brains. Progranulin
immunoreactivity in a human
(a) and a rodent brain (b)
showing that although GRN
immunoreactivity is strongly
present in microglia (arrows in
b), neuronal punctate immuno-
reactivity is also characteristi-
cally present in the cortical brain
regions. c TDP-43 reactivity in a
FTLD patient showing that
TDP-43 reactivity is not only
absent in a cell with TDP-43
inclusion (“nuclear clearing”)
but is also absent to weak in
some cells without inclusions.
d Similar observations are also
made in rodent brain showing
highly variable TDP-43
expression in the nucleus.
Scale bar, 20 μm
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nucleus (Cruts et al. 2006). The third types are those where
the mutant transcript reaches the cytoplasm but leads to
nonsense-mediated decay due to frameshift or nonsense
mutations (Baker et al. 2006;M a q u a t2004). This type also
includes mutations in the Met start codon, which disrupt the
Kozak sequence and result in a substantial reduction in GRN
expression (Baker et al. 2006; Cruts et al. 2006;G a s se ta l .
2006). The fourth types are those where the protein is
mislocalized such as those caused by signal peptide
mutations (Mukherjee et al. 2006). The fifth class includes
GRN coding variants (Gass et al. 2006; van der Zee et al.
2007; Mukherjee et al. 2008) that might cause loss of
function of the mutant GRN by subtle structural changes, or
by reduced protein production or secretion (Shankaran et al.
2008).
And finally, a subtle loss of GRN levels could also result
from variants in the regulatory region of GRN or in cis or
transacting elements, and these might contribute as a
susceptibility factor for the development of FTLD-TDP in
individuals who do not carry GRN causal mutations
(Rademakers et al. 2008;G a l i m b e r t ie ta l .2010;C a r r a s q u i l l o
et al. 2010; Van Deerlin et al. 2010). For instance, GRN has
been shown to be regulated by microRNA (miRNA).
miRNAs are short RNA molecules that bind to the 3′-
untranslated region (UTR) of the target mRNA and silence
genes via mRNA degradation or, when the complementation
between the miRNA and target mRNA sequence is
incomplete, by preventing mRNA from being translated
(Bartel 2009). A common genetic variant (rs5848) located in
the 3′-UTR of GRN was shown to be a strong binding site
for miR-659 and significantly increased the risk of develop-
i n gF T L D - Ua n da l s oo fh i p p o c a m p a ls c l e r o s i st h a t
commonly accompanies many neurodegenerative processes
including FTLD (Rademakers et al. 2008; Dickson et al.
2010). Other miRNAs are also being described as those that
could potentially bind to GRN and regulate its levels
including miR-107 identified in a high-throughput experi-
mental microRNA assay (Wang et al. 2010).
Genome-wide association studies have also identified
FTLD-TDP-associated risk alleles. Importantly, these studies
led to the identification of TMEM106B, a single-pass
transmembrane protein that increases the risk of FTLD-TDP
by modulating GRN levels (Van Deerlin et al. 2010). Cellular
or tissue factors might also regulate GRN levels by
modulating its turnover. GRN processing into grn-peptides
by elastase is modulated by secretory leukocyte protease
inhibitor (SLPI) by either directly binding and blocking the
elastase or by sequestering grn-peptides from the enzyme
(Zhu et al. 2002). GRN and its grn-peptides might at times
have opposing functions (Zhu et al. 2002), and it would be
interesting to study factors that increase the levels or the
activity of elastase and/or SLPI that might in turn modulate
GRN levels in brain parenchyma thereby increasing the risk
of developing FTLD-TDP.
GRN Cell Signaling
While loss of GRN levels and/or its function might be central
to FTLD-TDP etiopathogenesis, which of these many
functions is most critical to disease remains unknown. A part
of this quandary is also that the signaling pathways involved
in GRN-mediated neuronal survival have not yet been
established. In one of the earliest experiments, GRN was
identified to abrogate the requirement for insulin-like growth
factor receptor 1 (IGFR1) for growth in vitro by promoting
cellproliferationinmouseembryonicfibroblastsderivedfrom
IGFR1 knockout mice (Xu et al. 1998). These cells were
otherwise unable to proliferate in response to not only IGF-1
but also other growth factors such as epidermal growth factor
and platelet-derived growth factor that are necessary to fully
progress through the cell cycle (Sell et al. 1994). Over-
expression of GRN or treatment with recombinant GRN was
also shown to activate phosphatidylinositol 3-kinase (PI3K)
and mitogen-activated protein kinase (MAPK) pathways in
non-neuronal primary cells and cancer cell lines (Zanocco-
Marani et al. 1999;M o n a m ie ta l .2006). This was recently
confirmed on non-neuronal cells derived from GRN
−/− mice
that allows studies of GRN signaling pathways without the
low-level continuous stimulation otherwise present in cells
where GRN alleles are intact (Kleinberger et al. 2010).
However, in neuronal cells, GRN signaling pathways were
shown to be subtly different from those known for non-
neuronal cells with preferential involvement of PI3K/Akt
signaling pathways and with baseline phospho-Akt levels
reduced in GRN
−/− neurons (Kleinberger et al. 2010). In
other cells such as bone marrow-derived macrophages, GRN
deficiency led to lipopolysaccharide-stimulated upregulation
of proinflammatory chemokines and cytokines such as
monocyte chemoattractant protein-1, CXCL1, IL-6, IL-12,
and, importantly, TNF-α,a sw e l la sd o w n r e g u a l t i o no fI L - 1 0
(Yin et al. 2010). These data suggested that GRN is involved
in quite disparate pathways.
The receptors of GRN have been equally inexplicable.
Earliest data from competitive binding experiments indicated
a long list of known growth factors and cytokines that were
unable to displace radiolabeled GRN binding to its putative
receptor, suggesting that the receptor for GRN might not be a
known tyrosine kinase receptor (Culouscou et al. 1993). Two
recent studies have suggested separate putative GRN
receptors. Utilizing a cleverly designed ligand-binding assay
and expression cloning screening in COS-7 cells, the C
terminus portion of GRN was shown to bind to sortilin (Hu
et al. 2010). Sortilin is a single-pass type I transmembrane
protein of the Vps10 family that is localized to the cell
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et al. 2008). Upon binding to GRN, sortilin–GRN complex is
rapidly endocytosed and delivered to lysosomes thereby
regulating the extracellular levels of GRN. Mice lacking
sortilin show up to fivefold elevation in brain and serum
GRN levels (Hu et al. 2010). Sortilin in complex with
p75NTR also performs proneurotrophin apoptotic signaling,
but GRN binding to sortilin does not seem to be modulated
by p75NTR (Hu et al. 2010). While the precise signaling
mechanisms involved in GRN–sortilin pathway are unknown,
these studies already indicate that sortilin is yet another
modulator of GRN levels in brain.
In another study, in a yeast two-hybrid cDNA library
screening, GRN was recognized to bind to tumor necrosis
factor receptor (TNFR) (Tang et al. 2011). The best known
TNFR ligand, TNF-α, is a trimeric protein encoded within
the major histocompatibility complex and shares a number of
common functions with GRN such as their major production
by cells of macrophage lineage, pleiotropic inflammatory and
growth modulatory functions, and involvement in wound
healing and cancer. GRN exerts its anti-inflammatory effects
through inhibition of TNF-TNFR-mediated NF-κBa n d
MAPK signaling by competitively binding to TNFR espe-
cially TNFR-2 present in bone marrow-derived macrophages
(Tang et al. 2011). It is possible that growth modulatory
properties of GRN are also due to negative regulation of TNF-
α signaling with both growth-enhancing and growth-
inhibitory properties depending upon the cellular context.
Such binding can also explain other phenotypes of FTLD. For
instance, TNF-α with a biphasic diurnal pattern contributes in
regulating the body’s circadian rhythm and modulating sleep
(Young et al. 1995), and significant circadian rhythm
problems and sleep disturbances are described in FTLD
patients (Anderson et al. 2009). Ongoing studies will show
what all TNFR–GRN interactions occur in frontocortical
brain regions, but it is very likely that in future, more multi-
ligand cell-surface receptors for GRN will be identified
providinguswitha moreglobalpicture ofGRNcell-signaling
pathways that are abrogated in FTLD-TDP.
TDP-43 Pathology: A Cause or Consequence
of Neurodegeneration?
An important research question for studies involving GRN
haploinsufficiency-led neurodegeneration and other TDP-43
proteinopathies is whether the mislocalization, cleavage, or
abnormalaggregation ofTDP-43 isa cause orconsequence of
the disease pathogenesis. This is because, as discussed earlier,
TDP-43 pathology is also present in other neurodegenerative
disorders (Dickson 2008). TDP-43 pathology is absent in
ALS cases due to SOD1 mutations (Mackenzie et al. 2007);
however, mutant SOD1 mouse model and other ALS mouse
models such as Wobbler mice (due to mutant Vps54 gene)
show upregulation, mislocalization, and accumulation of
TDP-43 in brain (Shan et al. 2009;D e n n i sa n dC i t r o n2009).
The fact that missense mutations in TDP-43 lead to ALS
(Sreedharanet al. 2008;V a nD e e r l i ne ta l .2008; Kabashi et al.
2008) and ALS–FTLD (Benajiba et al. 2009)i sav e r y
important argument in the favor of primary perturbations in
TDP-43 leading to disease on its own and a testimony of a
sufficiently upstream and central mechanism in FTLD-TDP.
In vitro studies on select ALS mutants have also shown their
abnormal mislocalization, aggregation, increased toxicity, and
sequestration of physiological TDP-43 (Winton et al. 2008;
Johnson et al. 2008; Barmada et al. 2010). Thus, it remains
unknown what is most central to TDP-43 pathology: a toxic
gain of one or more toxic properties of TDP-43 accumulation
or a loss of normal physiological TDP-43 function.
TDP-43 Pathology: A Loss-of-Function Mechanism?
One of the first suggestions of a possible loss of TDP-43
function was based on observations that cells harboring TDP-
43 cytoplasmic or nuclear inclusions in ALS and FTLD-U
patientslackedthediffusenuclearTDP-43staining,suggested
to be due to sequestration of the physiological TDP-43 within
the cellular aggregates. While the precise mechanism of
nuclear depletion of TDP-43 remains unstudied, the knowl-
edge that TDP-43 is crucial in processing of so many RNA
targetsmakesitunlikelythatlossofnuclearTDP-43wouldbe
without consequences on cell function and viability. A likely
loss of function in RNA processing as a key molecular event
in ALS and related disorders is also supported by identifica-
tion of dominant missense mutations in ALS patients in the
gene encoding FUS/TLS with which TDP-43 shares striking
structural and functional similarities (FUsed in Sarcoma/
Translocated in Liposarcoma) (Kwiatkowski et al. 2009; Vance
et al. 2009). Accordingly, loss of TDP-43 in experimental
studies is shown to be toxic to in vivo and cultured neurons.
For instance, knockout/knockdown of Drosophila TDP-43
results in locomotive behavior and reduced life span
accompanied by disturbed neuromuscular junctions and
decreased dendritic branching (Feiguin et al. 2009;L ue ta l .
2009). Similarly, homozygous disruption of murine TDP-43
( m T D P - 4 3 )i ss h o w nt oe m b r y o n i c ally lethal perhaps because
of defective outgrowth of the inner cell mass prior to
implantation (Wu et al. 2010; Sephton et al. 2010; Kraemer
et al. 2010). Heterozygous adult mice show subtle motor
disturbance and muscle weakness (Kraemer et al. 2010).
Surprisingly, however, the phenotype resulting from
TDP-43 knockout is mild compared to the phenotype
observed for transgenic mice overexpressing human TDP-43
(hTDP-43) showing a cell-autonomous ALS/FTLD-like neu-
rodegeneration with ubiquitin
+, and also occasionally TDP-
J Mol Neurosci (2011) 45:561–573 56543
+, accumulations (Kumar-Singh et al. 2009;W e g o r z e w s k a
et al. 2009; Wils et al. 2010). Sequestration of endogenous
mTDP-43 into these cellular aggregates does not occur in
transgenic hTDP-43 mouse models; however, these models
instead show a transgene dose-dependent decrease in the
endogenous mTDP-43 (Kumar-Singh et al. 2009;X ue ta l .
2010;I g a ze ta l .2011). This is proposed to be due to
autoregulation, an important internal adaptive mechanism for
several physiological processes with many proteins sensitive
for gene dosage being autoregulated. Transgenic overexpres-
sion of sufficiently homologous genes has also been shown to
lead to downregulation of endogenous transcripts/proteins as
observed with a high transgenic presenilin expression causing
a near shutdown of endogenous presenilin synthesis
(Thinakaran et al. 1997; Kumar-Singh et al. 2006). Similarly,
TDP-43 with crucial dose-dependent functions is also
autoregulated in part by directly binding and enhancing
splicing of an intron in the 3′ UTR of its own transcript,
thereby triggering nonsense-mediated RNA degradation
(Ayala et al. 2011; Polymenidou et al. 2011).
If indeed loss of endogenous mTDP-43 rather than an
increase in transgenically expressed hTDP-43 is pathogenic
in these mouse models, we need to seek answers to three
relevant questions. One, how much is the reduction of
endogenous TDP-43? In Thy-1 driven wild-type (Wt)
hTDP-43 homozygous TAR4/4 mice, ∼26% reduction of
mTDP-43 was observed by Q-RT-PCR in whole brain,
when normalized to Actb housekeeping gene (Kumar-Singh
et al. 2009). In contrast to neuron-specific Thy1 promoter, a
more ubiquitous TDP-43 expression by PrP promoter led to
∼70% decrease in mTDP-43 in the homozygous line (Xu et
al. 2010), and a similar decrease in forebrain of mice was
also observed in hTDP-43 overexpressing mice under
Camk2a conditional promoter (Igaz et al. 2011). While
absolute reduction of endogenous mTDP-43 is dependent
on levels of exogenous hTDP-43, the expression pattern of
the promoter in context of how the analysis is performed
also influences the readout. For instance, neuron-specific
Thy-1 lines show less suppression of endogenous tran-
scripts on a total brain analysis when compared to the PrP
lines where the expression is in both neurons and glial cells.
An added problem is also in choosing appropriate house-
keeping genes due to the extensive list of RNA that TDP-43
targets. Single cell protein analysis such as immunohisto-
chemistry can yield interesting results, but these are
complicated by the fact that endogenous TDP-43
expression varies between cells and, for reasons not
yet known, a near-complete absence of TDP-43 immuno-
reactivityisalsoobservedinaproportionofhealthyappearing
neurons and glial cells (Fig. 2c, d).
If we can assume that TDP-43 reduction indeed exceeds
50%, levels at which it can be causing considerable loss of
function, a next logical question would be how homologous
are hTDP-43 and mTDP-43 as the total TDP-43 levels are
elevated in these models? Interestingly, mTDP-43 is 96%
homologous to hTDP-43, and hTDP-43 completely rescues
a loss-of-function phenotype in flies with which it shows
only 46% homology (Feiguin et al. 2009). Finally, if
reduction of mTDP-43 is pathogenic on its own, then
overexpression of autologous TDP-43 should not be as
toxic. Interestingly, mice overexpressing mTDP-43 have
been made (Tsai et al. 2010) that show a remarkably similar
phenotype to hTDP-43-expressing mice (Wils et al. 2010).
These data thus suggest that a loss-of-function mechanism
at least with the phenotype observed in the TDP-43
overexpressing mice is less likely.
Nevertheless, as discussed earlier, it is highly unlikely
that sequestration of physiological TDP-43 within the
aggregates or the missense mutations within TDP-43 does
not cause any loss of function of the many diverse and
critical functions that TDP-43 executes (Buratti and Baralle
2008; Lagier-Tourenne et al. 2010). It is possible that loss
of function caused by specific TDP-43 mutations is
mechanistically divergent. For instance, ALS-associated
R361S, but not D169G, have been shown to alter formation
of stress granules that are important for RNA stability
during stress (McDonald et al. 2011).
TDP-43 in Neurodegeneration: A Gain of Function?
Genetically, a gain-of-aberrant-function mechanism is sug-
gested when both overexpression of the Wt protein and
dominant missense mutant protein lead to the same pheno-
type. This has been the case with many neurodegenerative
disorders with defects in causative genes such as APP in AD
or SNCA in Parkinson’s disease (PD) (Hardy and Selkoe
2002). While gross gene duplications have not been shown
for TARDBP, polymorphisms within the 3′ UTR region have
been identified that are suggested to increase TDP-43 levels
(Gitcho et al. 2009a). Moreover, gene expression studies
have shown an ∼1.5-fold increase in TARDBP mRNA levels
in both FTLD-U and FTLD-MND cases compared to
controls (Mishra et al. 2007), and preliminary Q-RT-PCR
analysis on limited GRN causal mutation carriers also
showed slightly higher TARDBP levels (Chen-Plotkin et al.
2008). In limited clinical studies, higher TDP-43 protein
levels were also observed in pathological samples of ALS
(Kabashi et al. 2008).
While further genetic and clinical proof of TDP-43
dosage in ALS/FTLD is awaited, animal models of TDP-43
have been constructed that also show a high degree of TDP-
43 dose-related toxicity. For instance, expression of Wt
hTDP-43 in Drosophila causes impaired locomotor activity
(Li et al. 2010), as well as paralysis and reduced life span
(Hanson et al. 2010). Similarly, as discussed above, over-
566 J Mol Neurosci (2011) 45:561–573expression of Wt hTDP-43 in mice causes a very rapidly
progressive paralysis reminiscent of human ALS in a dose-
dependent manner (Wils et al. 2010;T s a ie ta l .2010).
Overexpression of Wt TDP-43 in neurons in vitro (Barmada
et al. 2010) or in vivo (Tatom et al. 2009) also leads to cell
death independently of mutation. A TDP-43 dose-dependent
toxicity leading to an expected phenotype suggests a gain-of-
function mechanism in TDP-43-led proteinopathies.
Conversely,the molecular mechanismsbywhichdominant
missense mutations in TARDBP are pathogenic is more
complex. Most of the TDP-43 mutations clustered in the
glycine-rich C-terminal domain of the protein are missense
mutations (Fig. 1b) with the exception of a rare truncating
mutation (Sreedharan et al. 2008; Van Deerlin et al. 2008;
Kabashi et al. 2008;B e n a j i b ae ta l .2009). Surely, the
mutations could cause an altered protein binding or
specificity; however, these could also suggest a possible
gain-of-toxic property for mutant TDP-43. Studies of
proteinopathies in other neurodegenerative diseases like AD
(Aβ), FTLD-τ tau (tau), and PD (α-synuclein) are again
instructive. For example in AD, APP is abnormally processed
by mutations near the secretases that lead to increased
production of fibrillogenic Aβ42 or, when the mutations are
within the Aβ domain, alter the kinetics of Aβ aggregation
(reviewed in Van Broeck et al. 2007). While the molecular
basis for TDP-43 proteolysis and the effect of these missense
mutations on TDP-43 proteolysis are unknown, the ∼25-kDa
TDP-43 CTFs were recovered in detergent-insoluble urea
fractions of affected brain regions of FTLD-TDP and ALS
patients (Neumann et al. 2006;A r a ie ta l .2006). Over-
expression of TDP-43 CTFs of different lengths in cultured
cells produces cytoplasmic aggregates that are ubiquitinated
and phosphorylated, thus recapitulating the biochemical
properties of pathological TDP-43 inclusions (Igaz et al.
2009; Dormann et al. 2009;N o n a k ae ta l .2009; Zhang et al.
2009). In TDP-43 animal models, ∼25-kDa CTFs are also
producedandcorrelatewithdiseaseprogression(Wegorzewska
et al. 2009;W i l se ta l .2010). Interestingly, TDP-43 and its
CTFs are largely localized to neuronal nuclei in these models
(Wils et al. 2010) and fit well with a similar nuclear
localization of ectopically expressed TDP-43 in Drosophila
(Hanson et al. 2010). These data suggest that increased Wt
TDP-43 dosage could be pathogenic via a nuclear mechanism
(Wils et al. 2010).
Although CTFs could be toxic, full-length (FL) TDP-43
is also inherently aggregation-prone, and ALS-linked
mutations further increase the aggregating propensity of
the protein (Johnson et al. 2009; Dormann et al. 2009). In
both Wt and mutant TDP-43 mouse models, the FLTDP-43
was shown to be overrepresented compared to ∼25-kDa
CTF (Wils et al. 2010; Wegorzewska et al. 2009). Some
form of tissue modulation towards the precise TDP-43
being deposited is also suggested by preferential recovery
of FL TDP-43 from spinal cord, while TDP-43 CTFs were
more common in cortical brain regions (Igaz et al. 2008).
Equally interesting is the evidence that questions an
early role of TDP-43 aggregates in TDP-43 led toxicity. It is
clear from TDP-43 animal model studies that only in high
transgene-expressing lines were a minority of ubiquitin
+
aggregates also TDP-43
+ (Wils et al. 2010; Wegorzewska et
al. 2009; Xu et al. 2010); however, lower expressing lines
(Wils et al. 2010; Igaz et al. 2011) did not have aggregates
and yet showed neurodegeneration. Moreover, in the high
expressing TDP-43 Thy-1 mice, FLTDP-43 or the ∼25-kDa
CTF was also recovered in the more soluble TBS-X
fraction in serial solubilization assays (Wils et al. 2010)
and corroborated a recent study where de novo cleaved
CTFs within nucleus were cleared without aggregation
(Pesiridis et al. 2011). These data strongly support the idea
thatcellularaggregateformationmightnotbeaprerequisitefor
the neurodegeneration observed in TDP-43 proteinopathies
although they contribute to disease progression as has been
suggested for mutant SOD1 (Karch et al. 2009). Notwith-
standing the precise loss- or gain-of-function mechanism,
these data all suggest that perturbations in TDP-43 dose or
structure are sufficient to cause cell-associated toxicity.
The Link Between GRN Loss and TDP-43 Pathology
Role of Caspases
The first proposal for a link between GRN haploinsufficiency
and TDP-43 pathology was suggested to be mediated via
caspases (Zhang et al. 2007). Caspase-mediated apoptosis is
recognized as a characteristic feature of FTLD (Su et al.
2000), and in prior studies, TDP-43 was identified as a
substrate for Fas-induced apoptosis (Van Damme et al.
2005). Also, consistent with withdrawal of the fetal calf
serum or major trophic factors causing a strong apoptotic
signal, sequestration of GRN by GRN-specific antibodies in
the select GRN-dependent cancer cell lines has been shown
to induce apoptosis (Kamrava et al. 2005;H ee ta l .2002).
Recently, Zhang et al. (2007) while silencing GRN in two
immortalized cell lines by a GRN-specific siRNA noticed a
dramatic caspase activation and caspase-mediated TDP-43
fragmentation into ∼25- and ∼35-kDa CTFs. However, three
subsequent studies did not confirm these data on similar
immortalized cell lines utilizing a battery of GRN-specific
siRNAs (Shankaran et al. 2008; Dormann et al. 2009;
Kleinberger et al. 2010). One study also utilized fibroblasts
derived from Grn
−/− embryos to circumvent the problem of
typical ∼80% of cells being targeted in siRNA experiments
but saw no effect on caspase activation/apoptosis or TDP-43
fragmentation (Kleinberger et al. 2010). GRN deficiency,
however, caused an expected anti-proliferative effect in these
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GRN significantly impacts on cell proliferation, it is not
sufficient to cause appreciably increased apoptosis in
proliferating cells. These data are consistent with the premise
that transient cell growth arrest in certain situations is
protective against apoptosis.
Studies on in vivo neurons have also not shown
significant activation of caspases, appreciable apoptosis,
or TDP-43 pathology in zebrafish model and GRN
knockout (Grn
−/−) mouse models (Shankaran et al. 2008;
Ahmed et al. 2010; Wils et al., submitted). Absence of any
signs of increased apoptosis could be due to increased
clearance of apoptotic cells by increased macrophage
activity as has been shown to occur in the development of
Caenorhabditis elegans (Kao et al. 2011). However, in
mixed embryonic Grn
−/− cortical cultures that also contain
microglia, an increased caspase activity accompanied
decreased cellular viability and subtle increase in ∼25-kDa
CTFs; however, these TDP-43 fragments did not become
insoluble or abnormally phosphorylated (Kleinberger et al.
2010). Caspase activation and ∼25-kDa CTFs have also
been observed in acute ischemic stroke model, but again
these TDP-43 fragments did not progress to abnormal
phosphorylation or insolubilization (Kanazawa et al. 2011).
Lastly, pathological TDP-43 CTF purified from FTLD-TDP
brains are shown to extend from amino-acid Arg-208, while
the predicted caspase-derived ∼25-kDa CTFs are shorter,
beginning at Val-220. These data suggest that while
caspase-derived TDP-43 CTFs might not be the initiating
link between GRN and TDP-43, some caspase-mediated
TDP-43 fragmentation could be expected in the course of
the disease contributing to the disease progression.
Role of Subtle Cell Stress
Accumulating data suggest that GRN loss might cause
increased cellular stress, that, on its own, can also lead to
cellular dysfunction and initiate TDP-43 pathology. GRN
mediates stress response caused by microenvironmental
stressors such as hypoxia or mild acidosis by increasing
GRN expression from cultured fibroblasts that do not
express GRN in vivo (Guerra et al. 2007). Treatment with
GRN in physiological concentrations also protected cells
from apoptosis induced by extreme acidosis (Guerra et al.
2007). Moreover, while GRN expression is upregulated in
microglia in a variety of neurodegenerative disorders
(Daniel et al. 2000; Baker and Manuelidis 2003), increased
GRN expression is also observed within neurons (Malaspina
et al. 2001; Irwin et al. 2008). Interestingly, miR-107, which
was previously implicated in AD pathogenesis, modulates
GRN levels (Wang et al. 2010), and a significant upregula-
tion of Grn was also shown in AD mouse models by
transcriptomic analyses (Pereson et al. 2009). In these
models, GRN reactivity was mostly observed within micro-
glia; however, neurons also showed increased GRN expres-
sion, especially those in the vicinity of dense-core plaques
known to be stressful to surrounding neurons (Pereson et al.
2009). Moreover, GRN secreted by microglia has been
proposed to be internalized by sortilin mostly localized on
neurons, suggesting that GRN upregulation could partly be
involved in the neuronal stress response (Hu et al. 2010). In
support of these data, Grn
−/− mouse models show signs of
increased brain aging such as accelerated neuronal lip-
ofuscinosis and ubiquitination (Ahmed et al. 2010; Wils et
al. 2008). Moreover, although no increased apoptosis or
caspase reactivity was observed in these mouse models
(Ahmed et al. 2010;W i l se ta l .2008), the finding that Grn
−/−
neurons, when extruded to in vitro cultures thereby
challenging them with stress associated with such a process,
show increased apoptosis and are rescued by exogenous
treatment of synthetic GRN, is interesting (Kleinberger et al.
2010). Taken together, these data suggest that GRN is a
trophic factor essential for neuronal survival during stressful
conditions and plays a key role in maintaining neuronal
function during aging (Ahmed et al. 2010;W i l se ta l .2008).
Grn
−/− mouse models also show abnormalities in ubiqui-
tin–proteasome (Ub–Pr) and lysosomal pathways, a charac-
teristic feature of FTLD-TDP (Lehman 2009; Kumar-Singh
and Van Broeckhoven 2007). Other genes involved with
FTLD-TDP also have a direct role in Ub–Pr and lysosomal
functions. For instance, almost all cellular activities of VCP
are directly or indirectly regulated by the Ub–Pr system, and
FTLD-TDP-associated mutant VCP leads to endoplasmic
stress and decreased proteasome activity (Gitcho et al.
2009b). Similarly, yeast CHMP2B is involved in transmem-
brane protein sorting and trafficking along late endosomes to
multivesicular bodies and lysosomes. Dysfunction of these
components results in the inability of the multivesicular
bodies to internalize membrane-bound cargo and results in
poor protein turnover (Babst et al. 2002). The putative GRN-
receptor sortilin is also suggested to play an important role in
lysosomal degradation and turnover of many proteins,
including perhaps TDP-43 (Hu et al. 2010).
While GRN deficiency causes cell stress or increases
susceptibility to cellular stressors due to poor protein
turnover, cellular stress alone was also shown to alter
TDP-43 solubility. Staurosporine-induced apoptotic stress
in HeLa cells has been shown to cause formation of
insoluble aggregates consisting of TDP-43 FL and CTFs
(Dormann et al. 2009). Similarly, proteasomal blocking in
cultured neurons by MG132 also showed a decreased
solubilityofFLTDP-43andanincreasedTDP-43cytoplasmic
accumulation, which was consistently higher in GRN
−/−
neurons (Kleinberger et al. 2010). Interestingly, overexpres-
sion of TDP-43 or its fragments at physiological levels has
not been shown to aggregate unless cells encounter another
568 J Mol Neurosci (2011) 45:561–573“hit” such as those caused by cell stressors (Pesiridis
et al. 2011). Recent data also suggest that TDP-43 itself
might have an important role in assembly and mainte-
nance of stress granules following oxidative stress
(McDonald et al. 2011). Stress granules are aggregations of
proteins and RNAs that appear when the cell is under stress
and helps to protect RNAs from harmful conditions.
Whether this activity is tweaked by GRN remains to be
shown.
Conclusions and Future Directions
In conclusion, the current evidence strongly implicates TDP-
43asakeymoleculeinthepathogeniccascadeofFTLD/ALS.
It is also clear that causal mutations in GRN are loss-of-
function mutations. Elucidation of the GRN function(s) that
are most central to frontotemporal neurons is an important
prerequisiteindecipheringunderlyingdiseasemechanismand
developing targeted therapies. The current knowledge sug-
gests that GRN deficiency, although not sufficient to cause
apoptosis in vivo, increases susceptibility to cellular stressors,
and in combination with other disease modulators, these
perturbations could cause TDP-43 to mislocalize and become
insoluble. Learning from research carried out for other
neurodegenerative diseases, it is very likely that TDP-43
toxicity involves both a loss of its multiple functions on RNA
processing as well as a toxic gain of function in disparate but
convergent pathways. TDP-43-mediated gain of toxic
function could initially involve a malfunction due to the
soluble forms of TDP-43, and perhaps in later part of
the disease, TDP-43-containing aggregates might also
contribute by increasing cellular stress generally associ-
ated with accumulating misfolded proteins. Recent
identification of two putative GRN receptors will also
help to elucidate how GRN is regulated by sortilin and
how some of the functions of GRN, likely the
inflammatory ones, could be mediated by its interaction
with TNF-α. While involvement of these receptors in
disease pathogenesis should be thoroughly investigated,
search for other cell-surface proteins, with which GRN
or its grn-peptides interact with intermediate-to-high
affinities, should also be prioritized to provide us with
am o r ec o m p l e t ep i c t u r eo fd i s e a s ep a t h o g e n e s i s .
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